-$0.91 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter

Equities analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will announce ($0.91) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Audentes Therapeutics’ earnings. The highest EPS estimate is ($0.84) and the lowest is ($1.02). Audentes Therapeutics reported earnings of ($0.82) per share in the same quarter last year, which suggests a negative year over year growth rate of 11%. The firm is scheduled to issue its next earnings results on Thursday, March 14th.

According to Zacks, analysts expect that Audentes Therapeutics will report full year earnings of ($3.39) per share for the current fiscal year, with EPS estimates ranging from ($3.60) to ($2.99). For the next fiscal year, analysts expect that the company will post earnings of ($3.79) per share, with EPS estimates ranging from ($4.59) to ($3.18). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.09). During the same quarter last year, the company posted ($0.88) earnings per share.

BOLD has been the topic of several analyst reports. ValuEngine cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 12th. Wedbush reduced their target price on Audentes Therapeutics from $52.00 to $49.00 and set an “outperform” rating on the stock in a report on Monday, October 8th. BidaskClub cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 25th. Finally, Guggenheim initiated coverage on Audentes Therapeutics in a report on Tuesday, October 9th. They issued a “neutral” rating on the stock. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $36.00.

In other Audentes Therapeutics news, VP Suyash Prasad sold 10,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $36.88, for a total transaction of $368,800.00. Following the transaction, the vice president now directly owns 100 shares in the company, valued at approximately $3,688. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew R. Patterson sold 12,952 shares of the stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total value of $518,080.00. Following the transaction, the chief executive officer now owns 12,952 shares in the company, valued at $518,080. The disclosure for this sale can be found here. Insiders have sold a total of 77,039 shares of company stock worth $2,925,260 over the last 90 days. Company insiders own 6.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in shares of Audentes Therapeutics by 4.5% during the 3rd quarter. BlackRock Inc. now owns 2,567,986 shares of the biotechnology company’s stock worth $101,667,000 after buying an additional 109,815 shares in the last quarter. Redmile Group LLC boosted its holdings in shares of Audentes Therapeutics by 70.3% during the 2nd quarter. Redmile Group LLC now owns 2,228,656 shares of the biotechnology company’s stock worth $85,157,000 after buying an additional 920,130 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Audentes Therapeutics by 0.8% during the 3rd quarter. Jennison Associates LLC now owns 1,028,668 shares of the biotechnology company’s stock worth $40,725,000 after buying an additional 8,112 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Audentes Therapeutics by 3.0% during the 3rd quarter. Victory Capital Management Inc. now owns 761,361 shares of the biotechnology company’s stock worth $30,142,000 after buying an additional 22,120 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Audentes Therapeutics by 40.3% during the third quarter. Alliancebernstein L.P. now owns 660,281 shares of the biotechnology company’s stock worth $26,141,000 after purchasing an additional 189,825 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Shares of BOLD stock opened at $24.00 on Wednesday. Audentes Therapeutics has a one year low of $19.62 and a one year high of $46.18.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: How analysts view the yield curve

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply